All the news Showing 10 of 46 articles from: Access to medicines & diagnosticsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Two-thirds of people with HIV/HCV co-infection in Southeast Asia in need of HCV therapy Michael Carter / 15 March 2017 Almost two-thirds of people with HIV/hepatitis C virus (HCV) co-infection in Asia are in need of HCV therapy with a fifth of people having cirrhosis, investigators report in the Journal of Viral ... New hepatitis C infections among HIV-positive gay men drop by half after direct-acting antiviral roll-out in Netherlands Liz Highleyman / 17 February 2017 A little more than a year after the Netherlands instituted a policy allowing unrestricted access to direct-acting antivirals for the treatment of hepatitis C, researchers have already seen a dramatic decline in acute ... US Veterans Affairs and Australia show potential for rapid elimination of hepatitis C Keith Alcorn / 15 November 2016 If sufficient money is available to pay for direct-acting antivirals (DAAs), the US Veterans Affairs (VA) could cure the majority of veterans under its care of hepatitis C within three years, and ... Generic hepatitis C drugs purchased online achieve high cure rates Keith Alcorn / 27 October 2016 Use of generic versions of direct-acting antivirals resulted in very high cure rates for people who obtained the products through three buyers’ clubs, indicating that the generic products are effective, according to three ... Inexpensive interventions can boost engagement with key stages of viral hepatitis care continuum Michael Carter / 14 October 2016 Several cheap interventions can significantly boost engagement with the continuum of care for viral hepatitis, a systematic literature review and a series of meta-analyses published in The Lancet Infectious Diseases show. Programmes led by ... HCV treatment is effective and may work as prevention for people who inject drugs Liz Highleyman / 19 September 2016 Hepatitis C treatment for people who inject drugs is as safe and effective as it is for non-drug-users – with cure rates exceeding 90% – and treating enough people in this population could ... INHSU 2016 opens with focus on hepatitis C prevention and treatment for people who inject drugs Liz Highleyman / 08 September 2016 The 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016) got underway yesterday with an overview of the epidemiology of hepatitis C virus (HCV) among people who inject drugs and ... Australia shows an alternative to rationing hepatitis C treatment Keith Alcorn / 06 June 2016 The Hepatitis C Trust has announced it is considering seeking judicial review of NHS England's decision to impose a cap on the number of people treated for hepatitis C in ... France to provide universal access to hepatitis C treatment Keith Alcorn / 01 June 2016 France will provide access to hepatitis C treatment with direct-acting antivirals to everyone diagnosed with hepatitis C from September 2016, and will begin to provide treatment to everyone with stage 2 fibrosis immediately, ... Only treating patients with cirrhosis with DAAs will have limited impact on HCV epidemic in England Michael Carter / 24 May 2016 Targeting new hepatitis C virus (HCV) direct-acting antivirals (DAAs) at patients with cirrhosis will substantially reduce short-term incidence of end-stage liver disease (ESLD) and liver cancer (HCC) in England, according to a model ... ← Prev12345Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Access to medicines & diagnostics Hepatitis C elimination Models of care Finance, funding & health economics National policy European policy International policy Activism and civil society Pharmaceutical industry Social issues Conference news Email bulletin archive